Stockscreener 앱 받기
0.8766
6.82%
0.0562
전일 마감가:
$0.8204
열려 있는:
$0.8204
하루 거래량:
98,576
Relative Volume:
0.20
시가총액:
$61.53M
수익:
-
순이익/손실:
$-30.15M
주가수익비율:
-0.9633
EPS:
-0.91
순현금흐름:
$-31.63M
1주 성능:
-3.53%
1개월 성능:
-17.33%
6개월 성능:
-58.86%
1년 성능:
-17.33%
1일 변동 폭
$0.8204
$0.881
1주일 범위
$0.7936
$0.95
52주 변동 폭
$0.7936
$2.75
Context Therapeutics Inc Stock (CNTX) Company Profile
명칭
Context Therapeutics Inc
전화
267-225-7416
주소
2001 MARKET STREET, PHILADELPHIA
CNTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
0.8766 | 61.53M | 0 | -30.15M | -31.63M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.52 | 113.70B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
682.91 | 75.52B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
663.46 | 39.78B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.41 | 35.34B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.61 | 29.05B | 3.30B | -501.07M | 1.03B | -2.1146 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-08 | 개시 | JMP Securities | Mkt Outperform |
| 2024-11-25 | 개시 | D. Boral Capital | Buy |
| 2024-05-16 | 개시 | Piper Sandler | Overweight |
Context Therapeutics Inc 주식(CNTX)의 최신 뉴스
Franklin Resources Inc. Acquires Additional Shares in Context Th - GuruFocus.com
Context Therapeutics Welcomes Andy Pasternak as New Chairman of the Board - MSN
Breakthrough in Cancer Treatment? Context Therapeutics Launches Phase 1 Trial for CLDN6-Targeted Therapy - MSN
Context Therapeutics Inc. (NASDAQ:CNTX) Short Interest Update - MarketBeat
Context Therapeutics’ (CNTX) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Context Therapeutics Stock Jumps Pre-Market On Analyst's Near 4x Upside View: Retail Pins High Hopes Too - MSN
Context doses first subject in Phase I cancer trial of CTIM-76 - Yahoo Finance
Context Therapeutics (NASDAQ:CNTX) Receives Buy Rating from D. Boral Capital - MarketBeat
Context Therapeutics Advances CTIM-76 in Clinical Pipeline - TipRanks
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76 - GlobeNewswire
Context Therapeutics Launches Phase 1 Trial for Novel Cancer Treatment CTIM-76 - StockTitan
Context Therapeutics Appoints Andy Pasternak as Chairman - TipRanks
Context Therapeutics appoints new chairman Andy Pasternak - Investing.com India
Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors - The Manila Times
Context Therapeutics Names Former Horizon Executive Andy Pasternak as Board Chairman - StockTitan
Pre-market Movers: AVGR, TIVC, ATNF, SLGL... - RTTNews
Context Therapeutics Inc. (NASDAQ:CNTX) Receives $6.80 Average Target Price from Brokerages - Defense World
Geode Capital Management LLC Cuts Stock Holdings in Context Therapeutics Inc. (NASDAQ:CNTX) - Defense World
Geode Capital Management LLC Purchases 70,070 Shares of DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World
JMP Securities Begins Coverage on Context Therapeutics (NASDAQ:CNTX) - Defense World
Context Therapeutics (NASDAQ:CNTX) Raised to Strong-Buy at Citizens Jmp - Defense World
MPM BIOIMPACT LLC Acquires Significant Stake in Context Therapeu - GuruFocus.com
Context Therapeutics (NASDAQ:CNTX) Stock Rating Upgraded by Citizens Jmp - MarketBeat
SpringWorks Therapeutics Stock Gets A RS Rating Lift - MSN
Aclaris Therapeutics Awards Stock Options to Attract Top Talent - MSN
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Context Therapeutics (NASDAQ:CNTX) Earns Outperform Rating from Analysts at JMP Securities - MarketBeat
Pre-market Movers: SANA, SLDB, JSPR, DRIO... - RTTNews
This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Analyst sees upside in Context Therapeutics stock—next-gen antibodies in spotlight - Investing.com Nigeria
Pre-market Movers: CDT, NARI, GDTC, NARI... - RTTNews
Philly’s year in biopharma: a look back at 2024 - MSN
State Street Corp Purchases 19,800 Shares of Context Therapeutics Inc. (NASDAQ:CNTX) - Defense World
Cal-Maine Foods IN (CALM-Q) QuotePress Release - The Globe and Mail
APLT INVESTOR NOTICE: Applied Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - The Malaysian Reserve
Short Interest in Context Therapeutics Inc. (NASDAQ:CNTX) Expands By 22.9% - MarketBeat
Context Therapeutics to Engage Investors at November Conferences - MSN
Applied Materials (AMAT-Q) QuotePress Release - The Globe and Mail
Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment - Benzinga
Unpacking Q3 Earnings: Netflix (NASDAQ:NFLX) In The Context Of Other Consumer Subscription Stocks - Yahoo Finance
Franklin Resources Inc. Buys New Stake in Context Therapeutics Inc. (NASDAQ:CNTX) - MarketBeat
Context Therapeutics Inc (CNTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.85%
4.93%
자본화:
|
볼륨(24시간):